Clinical Trials

Hepatology – Clinical Trials

The leading causes for Hepatic Cirrhosis and Liver Cancer are Viral Hepatitis including HBV and HCV, Alcohol and metabolic syndromes leading to obesity and NASH and Autoimmune disease.

The Monash Gastroenterology and Hepatology department has a leading clinical research program that ranges from Basic Science research through to Therapeutic trials and aims to reduce the burden of liver disease for our community, and ultimately save lives.

Some of our areas of focus are:

  • Viral Hepatitis
    The current focus for Hepatitis B, includes novel therapeutic approaches to restrict viral replication and cellular factors involved in HBV cccDNA formation. Many of the current Clinical Trials are in the early phase of research, Phase 1 and Phase 2.
  • Metabolic Syndrome
    The research focus for Non Alcoholic Fatty Liver Disease(NAFLD)  and steatohepatitis(NASH) is broad, including determining the prevalence and severity in our community and novel therapeutic approaches to reduce steatosis and both delay and reverse fibrosis. We are currently recruiting for both Phase 2 and Phase 3 clinical trials.
  • Autoimmune Hepatitis
    Therapeutic approaches to slow fibrosis
  • Advanced Liver disease
    The focus is on Cirrhosis and portal hypertension with novel approaches to decrease portal hypertension and slow progression of disease. In addition we are evaluating new technology to help manage patients with cirrhosis and its complications both in and out of hospital.
Book your COVID-19 vaccination -Find out more
+